Lynn G. Baird
Nessuna posizione attualmente
Profilo
Lynn G.
Baird worked as Senior VP-Regulatory Affairs & Quality Systems at Dyax Corp.
from 2001 to 2006.
Baird then worked as Vice President-Regulatory Affairs at Curis, Inc. before becoming SVP-Regulatory, Quality & Clinical Operations at CombinatoRx, Inc. from 2006 to 2009.
Baird also worked as Vice President-Regulatory Affairs at Reprogenesis, Inc. and as SVP-Regulatory, Quality & Clinical Operations at AlphaVax, Inc. Baird received an undergraduate degree from Virginia Polytechnic Institute & State University and a doctorate from Virginia Commonwealth University.
Precedenti posizioni note di Lynn G. Baird
| Società | Posizione | Fine |
|---|---|---|
CombinatoRx, Inc.
 CombinatoRx, Inc. Pharmaceuticals: OtherHealth Technology CombinatoRx, Inc. develops new medicines built from synergistic combinations of approved drugs. The company develops biopharmaceutical products. It conducts clinical trials and research programs. The company was founded by Alexis Borisy, Brent R. Stockwell, Michael A. Foley, Curtis T. Keith and Jacob D. Goldfield in 2000 and is headquartered in Cambridge, MA | Direttore Tecnico/Scientifico/R&S | 30/01/2009 |
| DYAX CORP. | Consigliere Generale | 01/04/2006 |
AlphaVax, Inc.
 AlphaVax, Inc. Pharmaceuticals: MajorHealth Technology AlphaVax, Inc. involves in clinical-stage biopharmaceutical company. It develops vaccine technology bio products. The firm products include Alphavax and pipleline bio products. It focuses on commercial potential of its alphavaccine vector technology in cancer immunotherapy. The company was founded in 1997 and is headquartered in Durham, NC. | Direttore Tecnico/Scientifico/R&S | - |
| CURIS, INC. | Consigliere Generale | - |
Reprogenesis, Inc.
 Reprogenesis, Inc. BiotechnologyHealth Technology Reprogenesis, Inc., located in Cambridge, Massachusetts developes tissue engineered therapies to treat unmet medical needs. The Company has proprietary technology utilizing the combination of cells and biomaterials to restore, repair or replace lost tissue or physiological function. The Company has a broad preclinical and clinical pipeline of products in the areas of urology, cardiovascular biology and plastic and reconstructive surgery. ChondrogelTM is its most advanced product | Consigliere Generale | - |
Formazione di Lynn G. Baird
| Virginia Commonwealth University | Doctorate Degree |
| Virginia Polytechnic Institute & State University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| CURIS, INC. | Health Technology |
| Aziende private | 4 |
|---|---|
CombinatoRx, Inc.
CombinatoRx, Inc. Pharmaceuticals: OtherHealth Technology CombinatoRx, Inc. develops new medicines built from synergistic combinations of approved drugs. The company develops biopharmaceutical products. It conducts clinical trials and research programs. The company was founded by Alexis Borisy, Brent R. Stockwell, Michael A. Foley, Curtis T. Keith and Jacob D. Goldfield in 2000 and is headquartered in Cambridge, MA | Health Technology |
Reprogenesis, Inc.
Reprogenesis, Inc. BiotechnologyHealth Technology Reprogenesis, Inc., located in Cambridge, Massachusetts developes tissue engineered therapies to treat unmet medical needs. The Company has proprietary technology utilizing the combination of cells and biomaterials to restore, repair or replace lost tissue or physiological function. The Company has a broad preclinical and clinical pipeline of products in the areas of urology, cardiovascular biology and plastic and reconstructive surgery. ChondrogelTM is its most advanced product | Health Technology |
AlphaVax, Inc.
AlphaVax, Inc. Pharmaceuticals: MajorHealth Technology AlphaVax, Inc. involves in clinical-stage biopharmaceutical company. It develops vaccine technology bio products. The firm products include Alphavax and pipleline bio products. It focuses on commercial potential of its alphavaccine vector technology in cancer immunotherapy. The company was founded in 1997 and is headquartered in Durham, NC. | Health Technology |
Dyax Corp.
 Dyax Corp. Pharmaceuticals: MajorHealth Technology Dyax Corp. engages in discovery, development and commercialization of novel biotherapeutics. The company was founded by Henry E. Blair in 1989 and is headquartered in Burlington, MA. | Health Technology |
- Borsa valori
- Insiders
- Lynn G. Baird
